In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
LCB01-0371 is a new oxazolidinone with cyclic amidrazone. In vitro activity of LCB01-0371 against 624 clinical isolates was evaluated and compared with those of linezolid, vancomycin, and other antibiotics. LCB01-0371 showed good activity against Gram-positive pathogens. In vivo activity of LCB01-0371 against systemic infections in mice was also evaluated. LCB01-0371 was more active than linezolid against these systemic infections. LCB01-0371 showed bacteriostatic activity against Staphylococcus aureus.
Jeong
Ji-Woong
JW
School of Life Science, Handong Global University, Puk-ku, Pohang City, Kyungbuk 791-708, Republic of Korea.
Jung
Sung-Ji
SJ
Lee
Hyun-Hee
HH
Kim
Yong-Zu
YZ
Park
Tae-Kyo
TK
Cho
Young-Lag
YL
Chae
Sang-Eun
SE
Baek
Sung-Yoon
SY
Woo
Sung-Ho
SH
Lee
Hyang-Sook
HS
Kwak
Jin-Hwan
JH
D000081:Acetamides / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D006094:Gram-Positive Bacteria / Q000187:drug effects; D000069349:Linezolid; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D023303:Oxazolidinones / Q000494:pharmacology* / Q000627:therapeutic use; D013211:Staphylococcus aureus / Q000187:drug effects; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D014640:Vancomycin; D000069349:Linezolid